Similar articles

• Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.

  Martinelli G, Malagola M, Ottaviani E, Rosti G, Trabacchi E, Baccarani M. Martinelli G, et al. Haematologica. 2004 Feb;89(2):236-7. Haematologica. 2004. PMID: 15003901 No abstract available.
• Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.

  Helbig G, Kyrcz-Krzemień S. Helbig G, et al. Am J Hematol. 2014 Jan;89(1):115. doi: 10.1002/ajh.23588. Epub 2013 Oct 15. Am J Hematol. 2014. PMID: 24009127 No abstract available.
• Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.

  Shen Y, Ren X, Ding K, Zhang Z, Wang D, Pan J. Shen Y, et al. Oncotarget. 2014 Nov 15;5(21):10407-20. doi: 10.18632/oncotarget.2090. Oncotarget. 2014. PMID: 25431951 Free PMC article.
• FIP1L1-PDGFRα-positive hypereosinophilic syndrome in childhood: a case report and review of literature.

  Farruggia P, Giugliano E, Russo D, Trizzino A, Lorenzatti R, Santoro A, D'Angelo P. Farruggia P, et al. J Pediatr Hematol Oncol. 2014 Jan;36(1):e28-30. doi: 10.1097/MPH.0b013e31827e6386. J Pediatr Hematol Oncol. 2014. PMID: 23337549 Review.
• [Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].

  Helbig G, Stella-Hołowiecka B, Hołowiecki J. Helbig G, et al. Pol Arch Med Wewn. 2005 May;113(5):490-7. Pol Arch Med Wewn. 2005. PMID: 16479834 Review. Polish. No abstract available.